Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Editas Medicine (EDIT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Editas Medicine to Participate in Investor Conferences in October

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in New York in October. Details are as follows:...

EDIT : 22.79 (-2.48%)
Another Positive Week for Stocks?

Another Positive Week for Stocks?

CRR : 6.80 (-3.13%)
BLUE : 143.30 (+8.81%)
EDIT : 22.79 (-2.48%)
ABBV : 91.04 (+0.41%)
EPZM : 17.70 (+1.14%)
Editas Medicine Receives EMA's Orphan Medicinal Product Designation for EDIT-101 for the Treatment of LCA10

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the European Medicines Agency (EMA) granted Orphan Medicinal Product designation to EDIT-101, a pre-clinical, CRISPR-based...

EDIT : 22.79 (-2.48%)
Flagship Pioneering Unveils Kaleido Biosciences and First Chemistry Platform for Microbiome Health

Flagship Pioneering, a fully-integrated life science innovation enterprise, today unveiled Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries that unlock the power...

SYRS : 16.50 (-2.08%)
AGIO : 71.12 (-0.32%)
MCRB : 10.81 (-1.64%)
EDIT : 22.79 (-2.48%)
Biotech Stocks on Investors' Radar -- Clovis Oncology, Dermira, Editas Medicine, and Endocyte

If you want a Stock Review on CLVS, DERM, EDIT, or ECYT then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Thursday, September 14, 2017, US markets...

DERM : 28.21 (-2.82%)
CLVS : 84.58 (+0.37%)
ECYT : 4.30 (-0.81%)
EDIT : 22.79 (-2.48%)
Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type 10 (LCA10)

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that the Company initiated a clinical natural history study of Leber Congenital Amaurosis type 10 (LCA10). LCA10 is...

EDIT : 22.79 (-2.48%)
Watching the Weather

Watching the Weather

PTCT : 17.91 (+0.28%)
EDIT : 22.79 (-2.48%)
RCL : 127.39 (-0.30%)
NOMD : 14.95 (+0.27%)
Editas Medicine to Participate in Morgan Stanley 15th Annual Global Healthcare Conference

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in a fireside chat at the Morgan Stanley 15 Annual Global Healthcare Conference on...

MS : 48.94 (+1.33%)
EDIT : 22.79 (-2.48%)
Editas Medicine (EDIT) Looks Good: Stock Moves Up 11.3%

Editas Medicine, Inc. (EDIT) moved big moved last session, as its shares rose over 11% on the day.

EDIT : 22.79 (-2.48%)
ALXN : 140.84 (+0.16%)
BUYINS.NET: EDIT SqueezeTrigger Price is $20.72. There is $117,581,437 That Short Sellers Still Need To Cover.

BUYINS.NET / www.buyins.net is monitoring Editas Medicine Inc. (NASDAQ:EDIT) in real time and just received an alert that EDIT is crossing above its primary SqueezeTrigger Price, the price that a short...

EDIT : 22.79 (-2.48%)
Editas Medicine Announces Second Quarter 2017 Results and Update

Leber Congenital Amaurosis type 10 (LCA10) product candidate EDIT-101 made significant progress toward clinical trials

EDIT : 22.79 (-2.48%)
J.P. Morgan Vice Chairman Stephen Berenson Joins Flagship Pioneering

Flagship Pioneering, a fully-integrated life science innovation enterprise, today announced that Stephen Berenson has joined the firm as executive partner. The former vice chairman of investment banking...

SYRS : 16.50 (-2.08%)
AGIO : 71.12 (-0.32%)
MCRB : 10.81 (-1.64%)
JPM : 97.84 (+2.07%)
EDIT : 22.79 (-2.48%)
Today's Research Reports on Stocks to Watch: Valeant Pharmaceuticals and Editas Medicine

NEW YORK, NY / ACCESSWIRE / May 31, 2017 / Editas Medicine's shares plunged yesterday after a published paper in the scientific journal Nature Methods revealed that the genome editing tool CRISPR/Cas9,...

EDIT : 22.79 (-2.48%)
VRX : 12.92 (-3.51%)
What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?

Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.

AZN : 34.65 (+0.12%)
EDIT : 22.79 (-2.48%)
PFE : 35.98 (-0.99%)
MKGAF : 112.4140 (-2.92%)
Why Editas Medicine (EDIT) Might Surprise This Earnings Season

Investors are always looking for stocks that are poised to beat at earnings season and Editas Medicine, Inc. (EDIT) may be one such company.

EDIT : 22.79 (-2.48%)
Editas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from its pre-clinical hematopoietic stem cell (HSC) program confirming the potential for CRISPR-based editing...

EDIT : 22.79 (-2.48%)
Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store?

Perrigo Company plc (PRGO) is expected to report first-quarter 2017 results later this month.

AUPH : 6.77 (-4.51%)
CDTX : 6.90 (-2.13%)
EDIT : 22.79 (-2.48%)
PRGO : 87.04 (-0.84%)
4 Drug Stocks Poised to Beat this Earnings Season

M&A and licensing deals as well as drug pricing issues are expected to remain in focus in 2017.

ENDP : 7.62 (-6.73%)
JNJ : 136.12 (-0.23%)
IMDZ : 10.10 (-7.76%)
LLY : 85.95 (-0.69%)
IONS : 61.15 (+3.47%)
EDIT : 22.79 (-2.48%)
GILD : 79.95 (-1.50%)
BIIB : 335.68 (-0.58%)
Editas Medicine to Present at Investor Conferences in May

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in May. Details are as follows:

EDIT : 22.79 (-2.48%)
Editas Medicine to Host Conference Call Discussing First Quarter 2017 Corporate Update and Results

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, May 15, 2017, at 5:00 p.m. ET to discuss a corporate update...

EDIT : 22.79 (-2.48%)

Van Meerten Stock Picks

5 Great Mid Caps
This morning I wanted to find 5 Mid Cap stocks with good price appreciation that still had current price momentum.
CC +0.97 , CGNX +1.90 , IPGP +0.59 , TTWO +0.20 , BCO -1.70
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Dec E-mini S&Ps ( ESZ17 unch) this morning are up +0.04% at a new all-time nearest-futures high and European stocks are also up +0.04%. Strength in commodity producing stocks is lifting the overall market with Nov... Read More

Chart of the Day

Chart of the Day

Tronox (TROX) is the Barchart Chart of the Day.  The titanium products company has a Trend Spotter buy signal, a Weighted Alpha of 200.44+ and gained 233.15% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures ended the Monday session with losses of 2 to 3 cents. The USDA Export Inspections report showed exports for the week of October 12 well below a year ago at just 12.7 mbu, and lagging the previous week by 44.59%. Export shipments for the ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart